Change Initiative
The Change Initiative addresses the most pressing challenges facing health systems around the world.
About the Initiative
The Change Initiative is a pioneering programme convened by the Office of Health Economics (OHE) — the world’s oldest independent health economics research organisation. Unique in its ability to bring industry, civil society, and academia together, the Change Initiative addresses the most pressing challenges facing health systems around the world.
We believe that lasting progress in health requires more than good intentions. It demands rigorous evidence, diverse perspectives, and a commitment to turning research into real-world change. That is what the Change Initiative exists to do.
How the Change Initiative works
The Change Initiative operates at the intersection of research, policy, and practice. We convene cross-sector coalitions of leading organisations — spanning pharmaceutical companies, multilaterals, civil society, and academia — to co-produce evidence that informs the live policy debates that matter most.
The model moves from system challenge to policy impact through four stages:
Partner
We form purposeful, cross-cutting collaborative partnerships that bring together the expertise, networks, and resources needed to tackle complex health challenges comprehensively.
Research
We facilitate transformative, evidence-led research grounded in health economics, co-developed with partners and validated by an independent Expert Council.
Solve
We translate research into actionable solutions: policy frameworks, financing models, and practical roadmaps that policymakers and industry can act on.
Change
We disseminate findings through targeted engagement — roundtables, briefings, webinars, media, and global forums — to drive evidence-based policy change where it matters.
Current programmes of work
Financing Prevention
Health systems worldwide face growing pressure from rising chronic disease, ageing populations, and escalating costs. Despite strong evidence for the cost-effectiveness of prevention, investment remains disproportionately low. This programme explores alternative funding and contracting models to tackle the root causes of underinvestment in preventive health.
US Policy Horizon Series
US pharmaceutical pricing reforms — from the Inflation Reduction Act to the Most Favored Nation policy — are reshaping global markets for innovation, pricing, and access. This multi-part research series examines the global implications of these changes and charts actionable pathways toward sustainable, equitable value models.